Special Issue

Antimicrobials Agents: Latest Advances and Prospects

Message from the Guest Editor

Antimicrobial resistance is considered by the World Health Organization to be one of the 10 global public health menaces facing humanity today, with serious medical, social and economic impacts. Therefore, finding new innovative and effective solutions to keep the pace with the antibiotic resistance developed by microbial pathogens is particularly challenging and represents an important objective of current biomedical research. We welcome the submission on the most recent research in the discovery of new antimicrobials and strategies used to fight antimicrobial resistance. This Special Issue will provide new insights on the discovery of new antimicrobials and strategies used to fight antimicrobial resistance; in this way, fitting into the scope of *Antibiotic*s (advances in research on new antibiotics: antibiotic resistance: qualitative and quantitative research exploring the determinants of antimicrobial use and resistance). Keywords: multidrugresistant pathogens; infectious diseases; antibiotic resistance; new antimicrobials; drug development; antimicrobial activity; structure-activity relationship (SAR); antimicrobial therapy

Guest Editor

Dr. Marius Stefan

BioActive Research Group, Faculty of Biology, University Alexandru Ioan Cuza of Iasi, Iasi, Romania

Deadline for manuscript submissions

closed (31 October 2025)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/145748

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

